Samsung Epis Holdings stock gets 104.3 billion won dividend inflow

Published on 11/13/2026 at 02:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Samsung Epis Holdings stock will receive an interim dividend from its wholly owned biotech subsidiary. The funds support operations and future drug investments.

Dividend channels cash to parent

Samsung Bioepis will transfer its interim distribution entirely to Samsung Epis Holdings.
The holding company plans to use the proceeds for operating flexibility and potential investments in novel drugs and biosimilars.
The payment follows the funding model announced when the corporate split was presented last year.

Samsung Epis, KR70126Z0002, Illustration mit AI erstellt.

Samsung Bioepis will pay an interim cash dividend of 104.31 billion won to Samsung Epis Holdings, its sole shareholder. The Herald Business reported the decision on Thursday, November 12, 2026, after Samsung Bioepis' board approved the distribution on Wednesday, November 11.

The payout equals 5,043 won per common share. The record date is Friday, December 4, and payment is scheduled for Friday, December 18, according to The Herald Business.

Cash supports holding structure

Samsung Epis Holdings owns all issued shares of Samsung Bioepis, so the full distribution will flow to the parent company. Samsung Bioepis represented 97.42 percent of the holding company's total assets on a separate basis at the end of 2025, making it the central operating asset of the group.

Management said the proceeds will support stable operations and financial flexibility while the holding company reviews investments in novel drugs and biosimilars. The dividend also follows the funding approach announced when the corporate split was unveiled last year, with subsidiary distributions identified as a primary source of funds.

Pipeline keeps competition active

Samsung Bioepis is expanding beyond established biosimilars as the industry moves toward more complex therapies. Its SB27 candidate targets pembrolizumab, the active ingredient in Keytruda, while the company is also developing products in areas including oncology, immunology and ophthalmology.

A BioSpectrum Asia analysis identifies Celltrion and Samsung Bioepis as the leading participants in South Korea's biosimilar market, with smaller players including Dong-A ST, LG Chem and GC Pharma. That competitive position gives the parent company exposure to a global growth market, but future returns remain linked to regulatory approvals, product launches and commercial uptake.

Business model and competitors

Samsung Epis Holdings presents itself as a biotechnology holding company focused on innovation in the biopharmaceutical market. Its core subsidiary, Samsung Bioepis, develops and commercializes biosimilar medicines across major therapeutic areas, while the holding structure is intended to channel subsidiary cash flows and support additional biotechnology opportunities. In South Korea, Celltrion is the closest large-scale competitor, while Dong-A ST and LG Chem represent smaller domestic rivals in the broader biosimilar development field.